These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 20210559

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.
    Nabipour I, Larijani B, Vahdat K, Assadi M, Jafari SM, Ahmadi E, Movahed A, Moradhaseli F, Sanjdideh Z, Obeidi N, Amiri Z.
    Menopause; 2009; 16(5):950-5. PubMed ID: 19387415
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Circulating osteoprotegerin and leptin levels in postmenopausal women with and without osteoporosis.
    Grigorie D, Neacşu E, Marinescu M, Popa O.
    Rom J Intern Med; 2003; 41(4):409-15. PubMed ID: 15526523
    [Abstract] [Full Text] [Related]

  • 8. Inverse Association Between Serum Osteoprotegerin and Bone Mineral Density in Renal Transplant Recipients.
    Hsu BG, Chen YC, Ho GJ, Shih MH, Chou KC, Lin TY, Lee MC.
    Transplant Proc; 2016 Apr; 48(3):864-9. PubMed ID: 27234754
    [Abstract] [Full Text] [Related]

  • 9. Bone mineral density and serum levels of soluble tumor necrosis factors, estradiol, and osteoprotegerin in postmenopausal women with cirrhosis after viral hepatitis.
    González-Calvin JL, Mundi JL, Casado-Caballero FJ, Abadia AC, Martin-Ibañez JJ.
    J Clin Endocrinol Metab; 2009 Dec; 94(12):4844-50. PubMed ID: 19897681
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Effects of Migu Tablet on bone mineral density, serum levels of osteoprotegerin and its ligand and bone metabolic markers in patients with postmenopausal osteoporosis].
    Dai Y, Shen L, Yang YP.
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2007 Aug; 27(8):696-9. PubMed ID: 17879531
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women.
    Rogers A, Saleh G, Hannon RA, Greenfield D, Eastell R.
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4470-5. PubMed ID: 12364420
    [Abstract] [Full Text] [Related]

  • 15. Serum osteoprotegerin correlates with age and bone mass in postmenopausal, but not in fertile age women.
    Mainini G, Incoronato M, Urso L, Scaffa C.
    Clin Exp Obstet Gynecol; 2011 Oct; 38(4):355-9. PubMed ID: 22268274
    [Abstract] [Full Text] [Related]

  • 16. The effects of osteoprotegerin (OPG) gene polymorphism in patients with ischaemic heart disease on the morphology of coronary arteries and bone mineral density.
    Celczyńska Bajew L, Horst Sikorska W, Bychowiec B, Wykrętowicz A, Wesoły J, Michalak M.
    Kardiol Pol; 2011 Oct; 69(6):573-8. PubMed ID: 21678294
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Differential bone metabolism between postmenopausal women with osteoarthritis and osteoporosis.
    Jiang LS, Zhang ZM, Jiang SD, Chen WH, Dai LY.
    J Bone Miner Res; 2008 Apr; 23(4):475-83. PubMed ID: 18052758
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.